Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹959.80up ₹22.80 (2.43%)BSE ₹955.75
Share price at the NSE close on 27 Oct 2026. Previous close ₹937.00.
27 Oct: open ₹939.80, high ₹965.90, low ₹931.40
52-week range of traded prices to 27 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,288 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 43.42
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 37.17
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.52%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,43,47353.0% delivered
Jubilant Pharmova board and management
55 filed, newest first. Page 1 of 2.
May 2026
22 May · Management
Sep 2025
Jul 2025
29 Jul · Management
May 2025
Oct 2024
Aug 2024
2 Aug · Management
May 2024
29 May · Management
Mar 2024
26 Mar · Management
26 Mar · Management
Feb 2024
Oct 2023
27 Oct · Management
Sep 2023
1 Sep · Management
Aug 2023
31 Aug · Management
31 Aug · Management
May 2023
30 May · Management
Mar 2023
8 Mar · Management
Feb 2023
4 Feb · Management
Jul 2022
Apr 2021
1 Apr · Management
Feb 2021
6 Feb · Management
Sep 2020
Oct 2019
Oct 2018
Jan 2018
17 Jan · Management
May 2017
Feb 2017
May 2016
Mar 2015
Feb 2015
20 Feb · Management
Mr. Rajiv Shah has been appointed as Company Secretary of the Company w.e.f. February 16, 2015. He shall also be the Compliance Officer of the Company.
Sep 2014
Sep 2013
3 Sep · Management
Mrs. Sudha Pillai has been appointed as Additional Director of the Company with effect from September 03, 2013. She will be an independent director.
Jun 2013
17 Jun · Management
Mr. S. Sridhar has been appointed as Additional Director of the Company with effect from June 15, 2013.
Apr 2013
15 Apr · Management
As per the Corporate Governance Voluntary Guidelines adopted by the Company, the Board had fixed a tenure of 9 years for Independent Directors. Accordingly, Dr Naresh Trehan and Mr Surendra Singh who have completed 9 years tenure have submitted their resignations.Dr Naresh Trehan has ceased to be director with effect from April 12, 2013 and Mr Surendra Singh has ceased to be director with effect April 15, 2013.8 Apr · Management
As per the Corporate Governance Voluntary Guidelines adopted by the Company, the Board had fixed a tenure of 9 years for Independent Directors. Accordingly, Mr. Hamidulla K. Khan, who has completed 9 years tenure has submitted his resignation. He has ceased to be director of the Company with effect from April 04, 2013.
Jul 2012
23 Jul · Management
Mr. Suresh Kumar has been appointed as Additional Director of the Company with effect from July 23, 2012.